

BISPECIFIC ANTIBODIES IN RELAPSED B-CELL NHL

7.26.24


Jason T. Romancik, MD Assistant Professor Winship Cancer Institute of Emory University






DLBCL BACKGROUND

- DLBCL is the most common subtype of lymphoma, ~25,000 cases/yr in US
- Many patients will be cured with with 1st line chemoimmunotherapy
- Prognosis remains poor for those who relapse, although survival increasing in in more recent treatment eras




TREATMENT ALGORITHM FOR RELAPSED DLBCL



Adapted from: Jason Westin, Laurie H. Sehn; CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?. *Blood* 2022; 139 (18): 2737–2746


BISPECIFIC ANTIBODIES FOR LYMPHOMA



- Bispecific abs bind and redirect cytotoxic activity of T-cells to malignant cells
- "Off-the-shelf", immediately available for use
- Currently approved for R/R DLBCL and FL
 - Encouraging activity in other lymphoma subtypes
- Major adverse effects:
 - Cytokine release syndrome
 - Neurologic toxicity
 - Hypogammaglobulinemia
 - Infection

DLBCL BISPECIFIC DOSING AND ADMINISTRATION

Glofitamab – IV infusion, fixed duration therapy



OTHER CONSIDERATIONS FOR DRUG ADMINISTRATION

Potential Benefits:

- Feasible for administration at community sites
- No REMS or FACT required
- No apheresis, cell processing required
- Opportunities for academic and community onc partnership

Considerations for use in community settings:

- Tocilizumab availability
- Healthcare provider training (nursing, hospitalist, ED)
- In-hospital monitoring logistics
- Afterhours plan, avoiding unnecessary ED visits

BISPECIFIC MONOTHERAPY EFFICACY IN R/R DLBCL


	Glofitamab	Epcoritamab	Odronextamab
Median Age, yr (range)	66 (21-90)	64 (20-83)	66 (24-88)
# Prior therapies	3 (2-7)	3 (2-11)	2 (2-8)
Prior CAR-T	33%	39%	29%
ORR (CR)	52% (39%)	63% (39%)	49% (31%)
Median PFS	4.9 mo	4.4 mo	4.4 mo
Median OS	11.5 mo	18.5 mo	-

Dickinson MJ, et al. *N Engl J Med*. 2022;387(24):2220-2231. Thieblemont C, et al. *J Clin Oncol*. 2023;41(12):2238-2247. Bannerji R, et al. *Lancet Haematol*. 2022;9(5):e327-e339.

BISPECIFIC MONOTHERAPY DURATION OF RESPONSE IN R/R DLBCL

Glofitamab

Epcoritamab



Those who achieve CR may have long-term remission, those who don't do poorly

Dickinson MJ, NEJM 2022; 387:2220-2231 Thieblemont C, J Clin Oncol 2023; 41(12):2238-2247


SAFETY OF BISPECIFICS IN DLBCL

	Glofitamab	Epcoritamab	Odronextamab
CRS (All), %	63	50	53
CRS (≥ Grade 3), %	4	3	1
ICANS (AII), %	8	6	3
ICANS (≥ Grade 3), %	3	1	1
Infection* (≥ Grade 3), %	15	15	23

*Opportunistic infections including PJP pneumonia and CMV reactiviation

EMERGING REAL-WORLD EFFICACY DATA

Swimmer plot describing glofitamab outcomes (months)



43 patients from 20 centers in Turkey

- ORR 37% (CR 21%)
- Median PFS 3.3 mo, OS 8.8 months
- Median DoR 6 months

Limited series so far, but in general, realworld outcomes inferior to what is reported in trials

Real-world data from US consortia coming soon

Birtas Atesoglu E, et al. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data. *Hematol Oncol.* 2023;41(4):663-673.

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

WHAT'S NEXT FOR BISPECIFIC ANTIBODIES IN DLBCL?

- MANY ongoing studies in a variety of clinical scenarios
- 1st line therapy
 - Phase 3 studies of bispecifics in combination with CHOP-based regimens
 - Bispecific therapy for older/unfit adults (anthracycline inegligible)
 - Bispecific + DA-EPOCH for HGBCL and Burkitt
- R/R DLBCL
 - Bispecific + salvage chemo in transplant eligible patients
 - Bispecific ab in the peri-CAR-T setting
 - Bispecific-containing combinations for multiply relapsed disease

SELECTED BISPECIFIC TRIALS IN R/R DLBCL

Phase I/II studies with bispecific antibodies in first-line tx for DLBCL

Drugs	NCT	Ν	Median age, y	ORR (CR), %
Mosun-CHOP	NCT03677141	40	65 (39-79)	82 (79)
Glofit-R-CHOP	NCT03467373	26	68 (26-84)	100 (89)
Epcor-R-CHOP	NCT04663347	24	65 (30-82)	100 (73)

Phase I/II study of epcoritamab combinations in R/R DLBCL (NCT04663347)

Drugs	Ν	Median age, y	Median prior tx	Median f/u, mo	ORR (CR), %
Epcor-R-DHAX	29	58 (28-75)	1 (1-3)	5.8 (1.5-11.4)	100 (86)
Epcor-GemOx	26	71 (47-87)	2 (1-13)	9 (1-15)	92 (60)

PHASE 3 DATA BEGIN TO EMERGE - STARGLO STUDY

R 2:1

Glofit-GemOx (n=183)

Glofitamab plus gemcitabine and oxaliplatin* Step-up dosing in Cycle 1, 30mg administered on Day 1 from Cycle 2 onwards

Cycles 1–8 (21-day cycles)

R-GemOx (n=91)

Rituximab[†] plus gemcitabine and oxaliplatin Administered on Day 1 of each cycle **Glofitamab** 30mg administered on Day 1 of each cycle

Cycles 9–12

Primary endpoint: Overall Survival

Enrolled mostly transplant ineligible patients 62% treated in 2nd line setting 10% ECOG PS of 2 ~50% had primary refractory disease 8% had prior CAR-T therapy

Patients R/R DLBCL (N=274)

- R/R DLBCL NOS after ≥1 prior systemic therapy
- Patients with one prior line must be transplant ineligible
- ECOG PS 0–2

Stratification factors


- Relapsed vs refractory disease[‡]
- 1 vs ≥2 prior lines of therapy

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

Abramson JS, et al.2024 European Hematology Association Congress; June 13-16, 2024; Madrid, Spain. Abstract LB3438.

STARGLOW STUDY – PHASE 3 GLOFITAMAB-GEMOX VS. R-GEMOX

- Primary endpoint met OS improved
 - 24-mo OS: 53% vs. 33%
- Secondary endpoints favor Glofit-GemOx:
 - CR rate: 58% vs. 25%
 - 12-mo PFS: 51% vs. 25%
- First Phase 3 study to demonstrate OS advantage with bispecific ab
- Implications for treatment sequencing?
 - For comparison, ZUMA-7 study 12mo PFS 52% for patients who received 2L CAR-T




Abramson JS, et al.2024 European Hematology Association Congress; June 13-16, 2024; Madrid, Spain. Abstract LB3438.

Ongoing studies of bispecific combinations in R/R DLBCL

Sa	alvage therapy	NCT05852717	Epcoritamab + R-GDP \rightarrow AutoHSCT or CAR-T	
	Peri-CAR T	NCT05633615	SWOG 2114: Mosunetuzumab, polatuzumab, or mosun+pola for patients with PR early after CAR-T	
Pe		NCT06071871	Pola + Obinutuzumab + glofitamab as a peri-CAR-T treatment strategy	
		NCT06238648	Epcoritamab vs. observation for patients not in CR after CAR-T	
_		NCT06213311	Axi-cel and glofitamab as second line therapy for R/R DLBCL	
M	ultiply relapsed	NCT04663347	Epcoritamab containing combinations for relapsed B-cell NHL	
	disease or transplant/CAR-T ineligible	NCT04970901	LOTIS-7: Loncastuximab containing combinations for relapsed DLBCL	
in		NCT04408638	Glofitamab + GemOx	


MOSUNETUZUMAB FOR FOLLICULAR LYMPHOMA

- Mosunetuzumab and epcoritamab are both FDA-approved for FL after ≥ 2 lines of therapy
- Ongoing efforts to combine bispecifics with other agents like lenalidomide
 - CELESTIMO study, NCT04712097
 - EPCORE FL-1, NCT05409066
- Bispecific or CAR-T for 3rd line therapy for FL?




Linton KM, et al. Lancet Haematol. 2024 Jun;13:S2352-3026(24):00166-2. Budde LE, et al. Lancet Oncol. 2022 Aug;23(8):1055-1065.

BISPECIFIC ANTIBODIES FOR OTHER B-CELL LYMPHOMA SUBTYPES




Glofitamab in R/R Mantle Cell Lymphoma

Mosunetuzumab + Len vs investigator's choice in R/R MZL



Epcoritamab +/- venetoclax in CLL and Richter's Syndrome



TAKE HOME MESSAGE

- Some patients have an excellent response to bispecific monotherapy, but there is much room for improvement
- Ongoing efforts to combine bispecific antibodies with other agents, move to earlier lines of therapy, and study in other lymphoma subtypes
- Bispecific antibodies are generally easier to administer than CAR-T
 - More appealing to administer in community setting
 - Careful consideration of staff training and side effect management is critical

Thank you!